A Phase II study to demonstrate the benefit of a new kind of anti-cancer treatment (PRAME Immunotherapy) for patients with a certain type of lung cancer, after removal of their tumor

The primary objective of this study is to evaluate the clinical efficacy of the PRAME ASCI versus placebo in terms of Disease-Free Survival (DFS).